These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19290378)

  • 1. Biospeciation of various antidiabetic V(IV)O compounds in serum.
    Jakusch T; Hollender D; Enyedy EA; González CS; Montes-Bayón M; Sanz-Medel A; Costa Pessoa J; Tomaz I; Kiss T
    Dalton Trans; 2009 Apr; (13):2428-37. PubMed ID: 19290378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the binding of oxovanadium(IV) to human serum albumin.
    Correia I; Jakusch T; Cobbinna E; Mehtab S; Tomaz I; Nagy NV; Rockenbauer A; Pessoa JC; Kiss T
    Dalton Trans; 2012 Jun; 41(21):6477-87. PubMed ID: 22476413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel V(IV)O-pyrimidinone complex: synthesis, solution speciation and human serum protein binding.
    Gonçalves G; Tomaz I; Correia I; Veiros LF; Castro MM; Avecilla F; Palacio L; Maestro M; Kiss T; Jakusch T; Garcia MH; Pessoa JC
    Dalton Trans; 2013 Sep; 42(33):11841-61. PubMed ID: 23677414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of vanadium(IV) with human serum apo-transferrin.
    Mehtab S; Gonçalves G; Roy S; Tomaz AI; Santos-Silva T; Santos MF; Romão MJ; Jakusch T; Kiss T; Pessoa JC
    J Inorg Biochem; 2013 Apr; 121():187-95. PubMed ID: 23411030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals.
    Liboiron BD; Thompson KH; Hanson GR; Lam E; Aebischer N; Orvig C
    J Am Chem Soc; 2005 Apr; 127(14):5104-15. PubMed ID: 15810845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of the carrier ligands of antidiabetic metal complexes with human serum albumin: a combined spectroscopic and separation approach with molecular modeling studies.
    Enyedy EA; Horváth L; Hetényi A; Tuccinardi T; Hartinger CG; Keppler BK; Kiss T
    Bioorg Med Chem; 2011 Jul; 19(14):4202-10. PubMed ID: 21696966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of VO2+ ion and some insulin-enhancing compounds with immunoglobulin G.
    Sanna D; Micera G; Garribba E
    Inorg Chem; 2011 Apr; 50(8):3717-28. PubMed ID: 21434616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vanadate complexes in serum: a speciation modeling study.
    Jakusch T; Dean A; Oncsik T; Bényei AC; Di Marco V; Kiss T
    Dalton Trans; 2010 Jan; (1):212-20. PubMed ID: 20023952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New developments in the comprehension of the biotransformation and transport of insulin-enhancing vanadium compounds in the blood serum.
    Sanna D; Micera G; Garribba E
    Inorg Chem; 2010 Jan; 49(1):174-87. PubMed ID: 19947643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Speciation of potential anti-diabetic vanadium complexes in real serum samples.
    Sanna D; Ugone V; Serra M; Garribba E
    J Inorg Biochem; 2017 Aug; 173():52-65. PubMed ID: 28499214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aqueous chemistry of the vanadium(III) (V(III)) and the V(III)-dipicolinate systems and a comparison of the effect of three oxidation states of vanadium compounds on diabetic hyperglycemia in rats.
    Buglyó P; Crans DC; Nagy EM; Lindo RL; Yang L; Smee JJ; Jin W; Chi LH; Godzala Iii ME; Willsky GR
    Inorg Chem; 2005 Jul; 44(15):5416-27. PubMed ID: 16022540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium(IV).
    Willsky GR; Goldfine AB; Kostyniak PJ; McNeill JH; Yang LQ; Khan HR; Crans DC
    J Inorg Biochem; 2001 May; 85(1):33-42. PubMed ID: 11377693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ternary oxovanadium(IV) complexes with amino acid-Schiff base and polypyridyl derivatives: synthesis, characterization, and protein tyrosine phosphatase 1B inhibition.
    Lu L; Yue J; Yuan C; Zhu M; Han H; Liu Z; Guo M
    J Inorg Biochem; 2011 Oct; 105(10):1323-8. PubMed ID: 21864810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectroscopic and potentiometric characterization of oxovanadium(IV) complexes formed by 3-hydroxy-4-pyridinones. Rationalization of the influence of basicity and electronic structure of the ligand on the properties of V(IV)O species in aqueous solution.
    Rangel M; Leite A; João Amorim M; Garribba E; Micera G; Lodyga-Chruscinska E
    Inorg Chem; 2006 Oct; 45(20):8086-97. PubMed ID: 16999406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoacid-derivatised picolinato-oxidovanadium(IV) complexes: characterisation, speciation and ex vivo insulin-mimetic potential.
    Esbak H; Enyedy EA; Kiss T; Yoshikawa Y; Sakurai H; Garribba E; Rehder D
    J Inorg Biochem; 2009 Apr; 103(4):590-600. PubMed ID: 19121544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative studies on the biospeciation of antidiabetic VO(IV) and Zn(II) complexes.
    Kiss T; Jakusch T; Hollender D; Enyedy EA; Horváth L
    J Inorg Biochem; 2009 Apr; 103(4):527-35. PubMed ID: 19114286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding patterns of vanadium to transferrin in healthy human serum studied with HPLC/high resolution ICP-MS.
    Nagaoka MH; Akiyama H; Maitani T
    Analyst; 2004 Jan; 129(1):51-4. PubMed ID: 14737583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vanadium complexes with mixed O,S anionic ligands derived from maltol: synthesis, characterization, and biological studies.
    Monga V; Thompson KH; Yuen VG; Sharma V; Patrick BO; McNeill JH; Orvig C
    Inorg Chem; 2005 Apr; 44(8):2678-88. PubMed ID: 15819553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivity and Speciation of Anti-Diabetic Vanadium Complexes in Whole Blood and Its Components: The Important Role of Red Blood Cells.
    Levina A; McLeod AI; Gasparini SJ; Nguyen A; De Silva WG; Aitken JB; Harris HH; Glover C; Johannessen B; Lay PA
    Inorg Chem; 2015 Aug; 54(16):7753-66. PubMed ID: 26230577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavior of the potential antitumor V(IV)O complexes formed by flavonoid ligands. 2. Characterization of sulfonate derivatives of quercetin and morin, interaction with the bioligands of the plasma and preliminary biotransformation studies.
    Sanna D; Ugone V; Pisano L; Serra M; Micera G; Garribba E
    J Inorg Biochem; 2015 Dec; 153():167-177. PubMed ID: 26281973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.